Alexion Pharma (ALXN) Tops Q2 EPS by 30c, Sales Beat; Raises Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Alexion Pharmaceuticals (ALXN) PT Raised to $168 at BMO Capital on 2Q Beat; 'Upside in Soliris Sales, Upward Revision to Sales Guidance'
July 28, 2017 10:31 AM EDTBMO Capital raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $168.00 (from $159.00) while maintaining a Outperform rating, following the company's second quarter earnings report.
Analyst M. Ian Somaiya notes a positive outlook, as the company delivered second quarter earnings per share and... More
Alexion Pharmaceuticals (ALXN) PT Raised to $170 at Leerink Partners
July 28, 2017 10:20 AM EDTLeerink Partners raised its price target on Alexion Pharmaceuticals (NASDAQ: ALXN) to $170.00 (from $136.00) while maintaining a Outperform rating. ALXN reported Q2 results and delivered a solid revenue and EPS beat vs. consensus. Management highlighted that the biggest contributors to the revenue growth were strong volume... More
